UBI Pharma Inc. (UNQ: 6562)
Health Care · Biotechnology · TW
NT$—
— today · — 1Y
UBI Pharma Inc. (UNQ: 6562) operates in the Biotechnology industry within the Health Care sector. The company is valued at $52.10M.
trading between 10.00 and 42.54.
Tweenvest scores UBI Pharma Inc. across four factors: quality 53/100, growth 0/100. Its strongest factor is quality.
6562 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $52.10M
- Revenue (TTM)
- $14.68M
- P/E
- —
- EPS
- -2.23
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- NT$42.54
- 52-week low
- NT$10.00
- Avg volume (3M)
- —
- Shares outstanding
- 118.19M
- Employees
- —
- Next earnings
- —
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $266.14 | +0.45% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $440.50 | +0.27% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.69 | +0.39% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.14 | +0.01% |
| argenx SEENXTBR: ARGX | $65.85B | €882.20 | -2.20% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $143.01 | -1.42% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.